Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Everyone have a happy, healthy and prosperous NEW YEAR
GO AFMD!!!!!!!! 2023 is yours for the asking
Okay it is time for more shareholders to get on this board and rally for a major up swing. All the signs show an upswing is here.
There was really NO need for the share price to crash. Even two major analyst agree and moved up the stocks upward value. 65% percent of the open float is owned by institutions who don't seem to have a clue about this company. This is great news for me as I will keep buying more shares as the share price tumbles. I thought the German people were very smart I guess not. We shall see.
Post # 278 below please do not open the PDF file. Someone added some malware to it so DO NOT CLICK ON IT. Sorry that a jerk had to ruin the link.
Equity Research
Company Update — December 2, 2021
Biotechnology A?med NV (AFMD)
AFMD: Virtual NDR Highlights Unique Technology, Pipeline Depth, Breadth and Near-Term Value Drivers
https://www.docdroid.net/A28l2M1/wells-fargo-afmd-research-12-2-21-1-pdf
Affimed: A small-cap biotech with room to run
Bucking the downward trend in biopharma in 2021, Affimed, a small-cap cancer immunotherapy company, has seen its shares actually rise by a healthy 19.8% this year. This tiny immunotherapy company has been able to swim against the current this year due to some truly eye-catching clinical trial data.
Last week, Affimed reported that its lead product candidate AFM13, when combined with a dose of natural killer cells, produced a 100% objective response rate in heavily pre-treated patients with recurrent or refractory CD30-positive lymphomas. AFM13 is thus on track to become the go-to therapy for later-line CD30-positive lymphomas; an indication that ought to be worth around $500 million to $600 million in sales per year.
To put these extremely preliminary revenue figures into context, Affimed currently sports a market cap of just $834 million. That's the key reason why Wall Street thinks this stock could more than double in value over the next 12 months.
Despite its relatively strong year, Affimed's novel anti-cancer platform still comes off as grossly undervalued at these levels. The company could eventually generate billions in sales and it stands out as a top buyout target right now.
https://www.fool.com/investing/2021/11/28/3-best-biopharma-stocks-to-buy-during-this-industr/
Affimed stock jumps 22% after reporting 100% ORR in Phase 1-2 lymphoma study
Nov. 22, 2021 7:43 AM ETAffimed N.V. (AFMD)By: Mamta Mayani
Affimed (NASDAQ:AFMD) soars 21.6% premarket after announcing interim clinical results from Phase 1-2 study, evaluating cord blood-derived natural killer (cbNK) cells pre-complexed with Affimed’s innate cell engager (ICE) AFM13.
As of October 31, 2021, a total of 18 patients with CD30-positive relapsed or refractory Hodgkin and non-Hodgkin lymphomas (16 and 2 patients, respectively) were treated with the novel combination of cbNK cells pre-complexed with AFM13.
As of the cutoff date, 16 of 18 patients had achieved an objective response to the treatment according to investigator assessment, with seven complete responses (CR) and nine partial responses.
100% objective response rate (ORR) was observed with a 42% CR rate in 12 patients with Hodgkin Lymphoma, after the 1st of 2 planned cycles at the recommended phase 2 dose of 108 cbNK cells/kg pre-complexed with AFM13.
No cases of serious adverse events such as cytokine release syndrome, neurotoxicity syndrome or graft-versus-host disease were observed.
Treatment was well tolerated with five reported cases of transient infusion related reactions after the monotherapy infusions of AFM13.
https://seekingalpha.com/news/3773189-affimed-stock-jumps-18-after-reporting-100-orr-in-phase-1-2-lymphoma-study
Lol What do you call the day before yesterday
Below post on conference was canceled.
Members, Thank you very much for your interest. Our sincere apologies but the doctor has a patient emergency, and we will need to reschedule this call. We will keep you posted. Thank you, Slingshot Insights
This one could be interesting for a novice and also the informed, plus it states "AFMD CALL IS FREE FOR ALL" and you are able to add questions before the call. I joined the call that will be in about 2 hours Pacific time-01:00 PM PDT-AFMD-Understanding the potential of AFM13 + NK Cells in CD30-positive lymphomas. Interview Goal
This conversation will discuss the current standard of care for lymphoma patients and the potential of AFM13. We'll ask how meaningful CRs are for patients who failed multiple lines of prior therapies, durability expectations for responses, and what line AFM13 might fall if successful. Sign up below: https://mailchi.mp/slingshotinsights/4-calls-today-on-si-bvhn-jnj-hospital-rev-cycle-cms-patient-surveys-1990719
mailchi.mp
4 Calls Today on SI: NVS, CRIS, CCXI & AFMD (Free to Join)
This morning AFMD Affimed initiated with a Buy at Truist
Truist analyst Srikripa Devarakonda initiated coverage of Affimed with a Buy rating and $10 price target. The analyst cites the company's phase 1 proof of concept data in two rare blood cancers, along with "futility hurdle" that Affirmed passed in pivotal trials, both of which support a peak sales opportunity of about
$500M. Devarakonda further notes the potential near-term upside for Affirmed from updated data from lead drug + NK cell combo likely to be presented at ASH2021.
Anyday now when it goes to $50 I am pretty sure youll be sorry you didnt follow my advise. Nuff said. They arent chasing amyloid plaçque. Sigmar1 receptor hold the key to CNS. Bye bye.
mrplmer
Alzheimer's is way to speculative for any company at this stage so I would take a pass on the stock this early on but appreciate the heads up. My father-in-law just was diagnosed with Alzheimer's and I wish there was a biotech play seriously close to some relief for those sufferers and their families.
I follow biotech and invest in the space heavily, so I stay on top of a wide range of bio`s. But Alzheimer's biotech research has not reached that investable point for me yet as there still is too much downside risk in the smaller bio`s research. GLTY with Anavex
If you are not "in" on Anavex then ya better find some powder. They might just have the cure for many CNS diseases. Their Blacarsimine is safe effective and works on Rett syndrome Parkinson's Disease and Dementia. Readouts in the next 2 months. Alzheimer's readout 2nd Q 2022. It agonizes the Sigmar1 receptor and creates cellular homeostasis. IT will be huge. Due Diligence important.
From below post:
Affimed: A new way to engage the immune system
Cancer immunotherapy has revolutionized the way oncologists approach the treatment of numerous liquid and solid tumors. Even so, the first generation of checkpoint inhibitors and genetically modified cellular therapies is far from 100% effective. Some of these novel treatments also come with a host of serious and potentially life-threatening side effects that limit their use in certain patient populations.
Affimed, a small-cap immunotherapy company, is trying to change this narrative by engaging the body's own immune system with a platform consisting of so-called "bi-specific antibodies" that active natural killer cells to attack tumor cells.
While the early stage results of the company's lead candidate, known as AFM13, have been impressive as a monotherapy from both an efficacy and safety standpoint, Affimed is also evaluating this therapy in combination with cord blood-derived natural killer cells, as well as checkpoint inhibitors. Wall Street, for its part, thinks this single biologic therapy could rake in well over $600 million at its peak.
Where do things stand now? Affimed is hoping to file its first regulatory application for AFM13 as a monotherapy indicated for patients with relapsed/refractory peripheral T-cell lymphoma. If things go according to plan, the biotech's first therapy could be on the market by perhaps 2023. Before then, however, there is a strong possibility that Affimed simply gets bought out. Big pharma has been on the hunt of late for early-stage cancer immunotherapy companies with unique assets, and Affimed fits that mold to a tee.
All told, Affimed's shares appear to be a downright steal at these levels. The company's market cap of $707 million arguably doesn't properly represent the promise of its anticancer platform -- even on a risk-adjusted basis. Affimed, after all, has already presented strong early stage results for its novel immunotherapy platform. Another major clinical update is reportedly slated to happen at a medical conference in the fourth-quarter of this year, according to the company's last quaterly update. Aggressive investors, therefore, might be wise to consider buying this undervalued biotech stock soon.
https://www.fool.com/investing/2021/10/18/2-biotech-stocks-poised-to-go-supernova-soon/
2 Biotech Stocks Set to Go Supernova Soon
https://www.fool.com/investing/2021/10/18/2-biotech-stocks-poised-to-go-supernova-soon/
Affimed (NASDAQ:AFMD) Receives $13.75 Average PT from Brokerages
Posted by Max Byerly on Jul 26th, 2021
Affimed (NASDAQ:AFMD) has been given an average rating of “Buy” by the six ratings firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $13.75.
https://www.tickerreport.com/banking-finance/7687643/affimed-nasdaqafmd-receives-13-75-average-pt-from-brokerages.html
Advancing Immuno-Oncology by believing in the potential of the immune system to restore patients’ innate ability to fight cancer
https://www.rdworldonline.com/advancing-immuno-oncology-by-believing-in-the-potential-to-restore-patients-ability-to-fight-cancer/
Affimed: Remaining Bullish Despite Study Discontinuation
https://seekingalpha.com/article/4438388-affimed-remaining-bullish-despite-study-discontinuation
Affimed N.V. (AFMD) CEO Adi Hoess on Q1 2021 Results - Earnings Call Transcript
https://seekingalpha.com/article/4437496-affimed-n-v-afmd-ceo-adi-hoess-on-q1-2021-results-earnings-call-transcript
$AFMD June presentation https://www.affimed.com/wp-content/uploads/Affimed-N.V._CP_June-2021.pdf
Wells Fargo Says
Affimed is an immune-oncology researcher in the biopharma world, looking into new therapies for cancer patients. The company’s ‘redirected optimized cell killing’ (ROCK) platform is used to develop innate cell engagers capable of reactivating the patient’s own immune cells to combat tumors. The company has 6 separate programs in its development pipeline, most in the preclinical stage of research. The company’s focus is on the treatment of hematological and solid tumors.
Of Affimed’s drug candidates, AFM13 is the first to have reached the clinical trial stage. The candidate has trials ongoing for the treatment of peripheral T cell lymphoma and CD30-postive T cell lymphoma, as well as transformed mycosis fungoides. Other lines of research are in earlier phases of development. AMF13 is a CD16A-based innate cell engager, and has shown promise of some therapeutic efficacy as well as a favorable safety profile.
In March, Affimed announced that it will be continuing REDIRECT, a Phase 2 study of AFM13 as a treatment for CD30-postivie T cell lymphoma. So far, the study has shown some anti-tumor response in both Cohort A and Cohort B of the patient base. Affimed’s recent program update also showed significant progress with AFM24, the company’s second most advanced program, now in a Phase 1 trial of its efficacy against solid tumors.
In his report on Affimed for Well Fargo, analyst Nick Abbott gives the stock an Overweight (i.e. Buy) rating and a $18 price target that indicates a potential for 62% upside in the year ahead.
Backing his stance, Abbott writes, “Our Overweight rating on AFMD reflects our view on AFMD’s approach to immuno-oncology (IO) with focus on the ROCK platform of innate cell engaging bispecific antibody development as a monotherapy, in combination with checkpoint inhibitors and in combination with cell therapy. Positive interim analysis of the registration-directed REDIRECT trial of AFM13 provides validation of the ROCK platform, in our view.”
Wall Street’s analysts are unanimous here, giving the stock 5 positive reviews in recent weeks for a Strong Buy consensus rating. The shares are priced at $10.42 and their $14 average target implies ~25% one-year upside.
https://www.tipranks.com/news/article/wells-fargo-says-these-2-stocks-could-spike-over-60-from-current-levels
* * $AFMD Video Chart 04-09-2021 * *
Link to Video - click here to watch the technical chart video
Here's Why Shares of Affimed Skyrocketed Today
https://www.fool.com/investing/2021/04/09/heres-why-shares-of-affimed-skyrocketed-today/?source=iedfolrf0000001
AACR: Germany's small NK cell player Affimed makes a big splash with early lymphoma data
https://endpts.com/aacr-germanys-small-nk-cell-player-affimed-makes-a-big-splash-with-early-lymphoma-data/
Heavy volume; investors are forward looking!
Affimed shares rise 9% on positive data from NK cells + AFM13 in solid tumors
The company will host a conference call/webcast on April 14 at 4:05 p.m. E.T.
Affimed Initiated at Outperform by Credit Suisse
Price Target Announced at $15.00/Share by Credit Suisse
Excellent news! > Investors are forward looking!
Affimed Sees Positive Initial Data in Lymphoma Treatment Trial
8:08 am ET April 9, 2021 (Dow Jones) Print
By Robb M. Stewart
Affimed NV said it has seen positive initial clinical data from a trial of an approach developed to treat patients with a form of lymphoma.
All four patients in the Phase 1 trial experienced significant disease reduction, with two complete responses and two partial responses, with an objective response rate of 100%, the immuno-oncology company said Friday. There were no observed events of cytokine release syndrome, neurotoxicity syndrome or graft-versus-host disease, it added,
News of the early data sparked a rally in Affimed's shares, pushing them up 28% in premarket trading after closing at $7.89 Thursday, up 36% so far this year.
The trial is looking at cord-blood-derived natural killer cells precomplexed with innate cell engager AFM13 in patients with recurrent or refractory CD30-positive lymphomas. It is an investigator-sponsored study at the University of Texas MD Anderson Cancer Center
"These initial results indicate AFM13 may have the potential to help NK cells target and destroy cancer cells," said Andreas Harstrick, chief medical officer of Affimed. "We plan to continue to develop and customize approaches that leverage the unique and differentiating features of our ICE molecules in combination with adoptive NK cell transfer to provide options for treating a variety of hematologic and solid tumors."
The company said its study is continuing enrollment of the second dose cohort.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
Book value $0.63 huge triple digit negative profit margins and cash flow. Only phase 1 just the beginning. Will have to hemorrhage money till completion. imho
Profitability
Profit Margin -175.03%
Operating Margin (ttm) -157.41%
Management Effectiveness
Return on Assets (ttm) -22.94%
Return on Equity (ttm) -114.04%
Income Statement
Revenue (ttm) 26.78M
Revenue Per Share (ttm) 0.34
EBITDA -41.33M
Net Income Avi to Common (ttm) -46.87M
Diluted EPS (ttm) -0.60
Balance Sheet
Total Cash Per Share (mrq) 1.31
Total Debt (mrq) 2.83M
Book Value Per Share (mrq) 0.63
Cash Flow Statement
Operating Cash Flow (ttm) -39.85M
Levered Free Cash Flow (ttm) -3.29M
$AFMD is screaming for the top after the company announced positive data from a clinical study of AFM13 in lymphoma. https://cnafinance.com/affimed-afmd-stock-rockets-on-data/
Wells Fargo Biotech Cell and Gene Therapy Companion o Newsletter. This week's themes include: continued fund-raising for cell and gene therapy; regulatory actions including first BCMA CAR-T product approval, a first CAR-T filing for adult acute lymphoblastic leukemia, IND approval for pre-loaded NK cells, Orphan Drug designation in TTR-amyloidosis; optimization of cell therapy including point-of-care, reversal of exhaustion; further exoneration of AVV as a driver of cancer, but caution over long-term toxicity from AAV9-SMN in mice with spinal muscular atrophy; funding of an academic CRISPR trial in sickle cell disease and pre-clinical data for a gene therapy addressing hemophilia A & B.
Highlights of the week include: 1) Applied Genetic Technologies Corporation (AGTC) partner, Bionic Sight disclosing positive data for BS01 in retinitis pigmentosa. 2) Emergence of potential point-of-care cell therapy competitor, Avalon GloboCare - relevant for Precigen (PEGN) and Ziopharm (ZIOP). 3) Gracell Biotechnologies (GRCL) agreement with Lonza to manufacture dual CD19/BCMA FasCAR-T, GC-012F.4) Announcement by uniQure (QURE) that independent investigation finds it highly unlikely that the case of hepatocellular carcinoma was caused by AAV. 5) Publication with senior author Guangping Gao that natural AAV sequences in tumors and adjacent tissue are not different from each other - relevant for QURE and Sangamo Therapeutics (SGMO). 6) IND approval for Affimed's (AFMD) first IND for pre-loaded NK cell therapy. 7) Autolus Therapeutic's (AUTL) obe-cel received PRIME designation for relapsed/refractory acute lymphoblastic leukemia (ALL). (8) Filing of an sBLA by Gilead for TECARTUS in adult ALL highlights obe-cel's superior safety profile. 9) FDA approved bluebird bio (BLUE) and BMY's BCMA CAR-T, ABECMA in a more restricted patient population than studied - relevant for AUTL, Cellectis (CLLS), Celyad Oncology (CYAD), Fate Therapeutics (FATE), GRCL. 9) Intellia Therapeutics (NTLA) received Orphan Drug designation in Europe for NTLA-2001 in TTR-amyloidosis. 10) CIRM will fund a CRISPR gene therapy trial in sickle cell disease at 3 University of California institutions - relevant for Beam Therapeutics (BEAM), BLUE, CRISPR Therapeutics (CRSP) & SGMO. 11) UCLA publishes pre-clinical data supporting clinical development of CD4 CAR-T for HIV; NIH publishes less encouraging data [this is science]. 12) Clinical vignette from Chinese glioblastoma patient treated with a B7H3 CAR-T published - relevant for FATE. 13) Columbia University publish pre-clinical data suggesting gain of toxic function data in mice receiving AAV9 SMN treatment for spinal muscular atrophy - relevant for Ionis Pharmaceuticals (IONS) if there is read through to NVS's ZOLGENSMA. 14) Pre-clinical gene therapy with a platelet restricted factor Xa is effective in hemophilia A & B - relevant to QURE/SGMO. 15) CAR-T exhaustion can be reversed in pre-clinical models with a single dose of dasatinib - relevant for all companies developing CAR-T using a high affinity/avidity scFv.
Notable Corporate Events
AGTC partner Bionic Sight reported initial data from a phase 1/2 study of BS01 in advanced stage retinitis pigmentosa (RP). The data demonstrated that all four patients, who were complete or near-completely blind, can now see light and motion. Additionally, 2/4 patients can now detect the direction of motion. Bionic expects to report additional data later in 2021. Recall, AGTC has the option to pick up the program when the phase 1/2 data are available.
Avalon GloboCare Corp and strategic partner Arbele, are collaborating with the University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center to advance the clinical development of point of care RNA-based autologous cell therapies using FLASH CAR technology. Avalon’s first FLASH CAR product candidate, AVA-011 targets CD19 and CD22 is on track to initiate a clinical study in B-cell leukemia and non-Hodgkin’s lymphoma – relevant for PEGN and ZIOP who use on-site point of care CAR-T manufacture leveraging Sleeping Beauty. PEGN and ZIOP use conventional DNA-CARs which integrate into the T cell genome while Avalon is using an RNA CAR which may be episomal and shorter lived.
GRCL signed an agreement with Lonza to manufacture FasTCAR products to support IND filing of dual BCMA/CD19 FasTCAR, GC-012F. Separately, GRCL announced enrollment of the first acute lymphoblastic leukemia patient into the registration-directed trial of GC007g in China. GC007g is an HLA-matched donor-derived allogeneic CD19 CAR-T product.
QURE announced the results of an independent investigation into the case of hepatocellular carcinoma (HCC) diagnosed in a patient in the HOPE-B trial. QURE noted that the independent investigation found it highly unlikely the HCC was caused by the company's AAV gene therapy etranacogene dezaparvovec (etra-dez).
Notable Regulatory/Clinical News
AFMD and partner NKMax America announced FDA IND clearance for a co-sponsored phase 1/2a dose escalation and expansion study evaluating AFMD’s EGFR/CD16A innate cell engager AFM24 in combination with NKMax America’s autologous NK-cell product SNK-01, currently in phase 1 testing, in patients with advanced/metastatic EGFR-expressing solid tumors.
AUTL announced receipt of PRIME designation for Obe-cel (AUTO1) in relapsed/refractory B-acute lymphoblastic leukemia (B-ALL) as well as recent listing of the MCARTY trial (NCT04795882) evaluating a modular CAR-T targeting BCMA alone or BCMA with CD19.
AUTL – Filing of an sBLA by GILD for TECARTUS highlights the superior safety profile of obe-cel (AUTO-1). With 1/4 and nearly 1/2 of TECARTUS-treated adult acute lymphoblastic leukemia patients suffering grade 3 or higher cytokine release syndrome (CRS) and neurotoxicity / immune cell associated neurotoxicity syndrome (ICANS) respectively at the 1M cell dose of ZUMA-3. By contrast, in 20 patients treated with obe-cel, AUTL reported no grade 3 or higher CRS and ICANS was limited to 4/20 patients, of which 3 cases were grade 1 and resolved within 24 hours.
AUTL – Chinese academics listed a phase 1 trial of a TRBC1 CAR-T in TRBC1+ve relapsed/refractory T cell leukemia. AUTL is conducting the LIbrA T1 trial of AUTO4 in TRBC1+ve T cell leukemia with interim data expected 2H21; AUTL expects to initiate clinical development of AUTO5 in TRBC2 T cell leukemia 2H21.
AUTL/CLLS/CYAD/ FATE & GRCL - we see the approved label for bluebird bio/ Bristol Myers Squibb's BCMA CAR-T, ABECMA for relapsed/refractory multiple myeloma setting a low bar for competitors. While ABECMA was studied in 4th line plus myeloma FDA gave the product a 5th line plus label. ABECMA’s blackbox warning includes hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) which occurred in 4% of patients overall increasing to 8% at the 450MM dose; approved CD19 CAR-T do not have an HLH/MAS blackbox warnings. In more recent BCMA trials, we note use of the IL-1 receptor antagonist, ANKINRA, potentially for HLH/MAS with 19% use in JNJ/Legend Biotech's cilta-cel CARTITUDE-I trial.
NTLA announced receipt of orphan drug designation from European Commission (EC) for Regeneron-partnered in vivo editing program NTLA-2001 for TTR amyloidosis (ATTR). The decision follows the initiation of the phase 1 study of NTLA-2001 in hereditary ATTR with polyneuropathy (hATTR-PN).
BEAM/BLUE/CRSP/EDIT - California Institute of Regenerative Medicine will support a phase 1 trial of CRISPR engineered SCD gene therapy to be conducted at The University of California, San Francisco (UCSF), UC Berkeley (UCB) and UC Los Angeles (UCLA).The 4-year study will include six adults and three adolescents with severe sickle cell disease. It is planned to begin this summer in Oakland and Los Angeles.
Notable Peer Reviewed Publications
FATE/CLLS – With both companies expected to announce programs outside of oncology we note UCLA scientists publish data for a 2nd generation anti-HIV1 CAR-T. UCLA’s use of engineered hematopoietic stem cells could be replaced by FATE’s induced pluripotent stem cells in our view. UCLA modified hematopoietic stem cells with a truncated CD4 CAR to target HIV envelope, that unlike the first gen CAR prevented HIV transmission as well as prevented IL-16 binding and potential non-specific CAR signaling while maintaining similar cytotoxicity against Env+ve cells. The use of 41BB as a costimulatory domain of the CAR, versus CD28 was essential for successful differentiation and improved anti-viral function. Suppression of viremia in untreated mice by the 2nd gen CAR was enhanced by combination treatment with ART which increased CAR-T persistence. The authors believe the 2nd gen CAR-T should be pursued as a clinical candidate. Separately we note an NIH manuscript describing the development of CAR-T against SIV. The studies failed to protect or gain control of viral spread. The authors identified optimal targets noting that while minimally expanded T cells were the most potent, generating large numbers was a challenge, one we note would not be an issue for an iPSC/allogeneic CAR-T. In addition, the authors observed that virus infected cells expressed Env protein for a relatively small fraction of the rapid viral lifecycle, and only towards the end when virus may be about to be released, an observation we interpret as requiring CAR-T persistence or the ability to re-dose.
AFMD should keep investors engaged over the next 15 months.
https://mattbiotech.substack.com/p/8-afmd-should-keep-investors-engaged?token=eyJ1c2VyX2lkIjoyMzUwODI2MywicG9zdF9pZCI6MzMzMTY4MjUsIl8iOiJONGVucyIsImlhdCI6MTYxNzYyMjA1OCwiZXhwIjoxNjE3NjI1NjU4LCJpc3MiOiJwdWItMjQ3MDA3Iiwic3ViIjoicG9zdC1yZWFjdGlvbiJ9.Wn2srFGmTJsw4Rvh-vNoCUNi_7YX9uNopW8OF6oOyGk&utm_source=substack&utm_medium=email&utm_content=share
Affimed (NASDAQ:AFMD) versus Spotlight Innovation (OTCMKTS:STLT) Critical Review
https://zolmax.com/investing/affimed-nasdaqafmd-versus-spotlight-innovation-otcmktsstlt-critical-review/5503524.html
Your in good company:
AFFIMED INSTITUTIONAL BUYING AND SELLING
https://www.marketbeat.com/stocks/NASDAQ/AFMD/institutional-ownership/
Point72 Asset Management, L.P. reports stake of 5.0%
One for the short crowd to take control. This is too many shorts for all Affimed has going:
Affimed (NASDAQ:AFMD) was the recipient of a significant increase in short interest in January. As of January 15th, there was short interest totalling 7,040,000 shares, an increase of 14.3% from the December 31st total of 6,160,000 shares. Based on an average daily volume of 1,660,000 shares, the days-to-cover ratio is currently 4.2 days.
Affimed stock opened at $5.74 on Friday. The stock has a market cap of $506.99 million, a PE ratio of -9.73 and a beta of 2.81. Affimed has a one year low of $1.42 and a one year high of $7.48. The stock has a fifty day moving average of $6.31 and a 200 day moving average of $4.60.
https://www.tickerreport.com/banking-finance/7035131/affimed-nasdaqafmd-short-interest-update.html
AFMD - Affimed Announces Pricing of $100,000,000 Public Offering of Common Shares
Followers
|
38
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
307
|
Created
|
09/16/14
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |